top of page

Intellectual Property & Licensing

Novilux has put in place formidable barriers to entry for competitors including: 

  

  • High number of issued patents with broad claims   ​

   

  • Significant internally developed trade secret IP and know-how in consumables, fluidics, assays, optics, signal and image processing, and alignment / fabrication techniques

  

  • New patent applications with allowed claims covering novel concepts incorporated into the Point-of-Care product

  

Novilux patents and out-licensing program ensure a strong and growing future for its technology. 

By the Numbers

57

Issued Patents

14

Individual Jurisdictions

18

Applications in process

3

Out-Licenses

Out-Licensing Agreements

Novilux has strategically out-licensed technology with royalty-based, straight cash, exclusive and non-exclusive agreements.

  • MilliporeSigma / Merck KGaA – Research tools. Multitudes of researchers around the world using SMC™ to discover new, clinically effective biomarkers.

  

  • Grifols – Blood screening. Next generation platforms in development using Novilux SMC™ technology.

  

  • Undisclosed – completed in late 2022, non-exclusive rights to use SMC™ technology in a limited field.

Grifols.png
Millipore Sigma 2.png
Undisclosed_edited_edited_edited.jpg

o  Key agreements in place expanding the use of Novilux SMC™ technology. 

bottom of page